Abstract CT268: Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors

作者
Anthony W. Tolcher,Nehal J. Lakhani,Meredith Ann McKean,Babar Bashir,Jason Timothy Henry,Andrae Lavon Vandross,Alexander I. Spira,Jennifer Brooke Valerin,Trupti Lingaraj,Katherine K. Kim,Wilmin P. Bartolini,Marissa Timothy,Katherine A. Kacena,David Damphousse,Jeffrey Ecsedy,Caroline Germa,Jason J. Luke
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_2): CT268-CT268 被引量:2
标识
DOI:10.1158/1538-7445.am2025-ct268
摘要

Abstract Background: The clinical utility of MEK inhibitors is limited to BRAF V600X mutant cancers and NF1 mutant neurofibromas due to early emergence of resistance and low therapeutic indices. IK-595, a novel MEK-RAF molecular glue, traps MEK in an inactive complex with all RAF isoforms and durably blocks MEK and ERK phosphorylation. IK-595 overcomes the key resistance mechanisms to approved MEK inhibitors including CRAF-mediated MEK reactivation and kinase independent CRAF activity. Moreover, the PK profile of IK-595 enables robust but intermittent pathway inhibition, which drives apoptosis in MAPK-pathway dependent cancers while minimizing toxicity to healthy cells. Methods: This is a phase 1, first-in-human, open-label, multicenter study to evaluate IK-595 as monotherapy in pts with RAS- or RAF-altered advanced solid tumors for whom there are no treatment options known to confer clinical benefit. The study consists of a Dose Escalation phase using a Bayesian Optimal Interval design, followed by a Dose Expansion phase. In Dose Escalation, IK-595 was administered orally at doses ranging from 0.5-8 mg on intermittent dosing schedules (QOD, Q3D, QW, and BIW). Study objectives included evaluation of safety, PK, PD, and antitumor activity (RECIST 1.1). Results: As of Jan 06, 2025, 51 pts enrolled in the Dose Escalation phase across 8 dose regimens. Median age was 61 years (range 35-84); 88% of pts had RAS mutations and 12% had RAF mutations; median number of prior lines of therapy was 3. More than half (53%) of the pts had a primary diagnosis of CRC, followed by pancreatic cancer (23.5%), and others (23.5%). The treatment was well tolerated and the most common treatment-related adverse events were grade 1 or 2 rash, diarrhea, nausea, fatigue, vomiting, and retinopathy. IK-595 exposure increased dose proportionally and the t½ was ∼24 hrs. Robust pERK inhibition was demonstrated in a blood PD assay. Saturating inhibition occurred with doses ≥1 mg 4 hrs after dosing. The durability of inhibition increased with increased dose; 6mg resulted in a PD response of ∼90% at 24 hrs and ∼80% at 72 hrs. Blood samples were collected to evaluate ctDNA dynamics and will be presented. The overall DCR was 44% (15/34) in disease-evaluable pts. Significant tumor reduction was observed in 5 pts; 2 cPRs occurred in KRAS G12D gastric (2 prior lines tx) and KRAS G12D ovarian cancer (3 prior lines tx including MEKi); 1 uPR occurred in KRAS G12R pancreatic cancer with liver metastases (1 prior line tx) with responses ongoing; 2 prolonged SD occurred in Class III BRAF mutant urothelial cancer (7 lines prior tx) for 29 weeks and KRAS G12D CRC (2 lines prior tx) for 30 weeks and ongoing. Conclusion: IK-595 is well tolerated in pts with low-grade skin and GI toxicities as the most frequently observed adverse events. Encouraging target inhibition and early antitumor activity in RAS- and RAF-altered solid tumors was observed. Clinical trial information: NCT06270082 Citation Format: Anthony W. Tolcher, Nehal J. Lakhani, Meredith McKean, Babar Bashir, Jason T. Henry, Andrae L. Vandross, Alexander I. Spira, Jennifer B. Valerin, Trupti Lingaraj, Katherine Kim, Wilmin Bartolini, Marissa Timothy, Katherine Kacena, David Damphousse, Jeffrey Ecsedy, Caroline Germa, Jason J. Luke. Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT268.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
王禹垚发布了新的文献求助10
1秒前
袋袋发布了新的文献求助10
1秒前
2秒前
NY发布了新的文献求助10
2秒前
lyj发布了新的文献求助10
2秒前
所所的应助被qd采纳,获得10
3秒前
4秒前
科研通AI6.3的应助被lmy采纳,获得10
4秒前
zhudaxia完成签到,获得积分10
6秒前
6秒前
6秒前
花痴的手套完成签到 ,获得积分10
6秒前
麦粑块发布了新的文献求助10
7秒前
小牛牛发布了新的文献求助10
7秒前
7秒前
9秒前
INT发布了新的文献求助10
10秒前
hyy发布了新的文献求助30
10秒前
研友_VZG7GZ的应助被李瑞程采纳,获得10
10秒前
小蘑菇的应助被醉熏的寄松采纳,获得10
11秒前
我是谁的应助被醉熏的寄松采纳,获得50
11秒前
zhudaxia发布了新的文献求助30
11秒前
领导范儿的应助被醉熏的寄松采纳,获得10
11秒前
慕青的应助被醉熏的寄松采纳,获得10
11秒前
无花果的应助被醉熏的寄松采纳,获得10
11秒前
Lucas的应助被醉熏的寄松采纳,获得10
11秒前
国服躺赢完成签到,获得积分10
11秒前
搜集达人的应助被醉熏的寄松采纳,获得10
12秒前
12秒前
桐桐的应助被醉熏的寄松采纳,获得30
12秒前
12秒前
12秒前
陈富贵完成签到,获得积分10
12秒前
13秒前
13秒前
13秒前
growl发布了新的文献求助10
13秒前
任亮亮发布了新的文献求助10
14秒前
逆光完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239